Who are Lurasidone tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Latuda©, Latuda (Lurasidone), Lurasidone Oral Capsule, Lurasidone 20, 40, 60, 80 mg, flexibly dosed, Lurasidone HC1, SAMIDORPHAN L-MALATE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lurasidone-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Lurasidone tablets — Competitive Intelligence Brief

Lurasidone tablets (Lurasidone tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry.

phase 3 Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT7 receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Lurasidone tablets (Lurasidone tablets) — Sumitomo Pharma (Suzhou) Co., Ltd.. Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lurasidone tablets TARGET	Lurasidone tablets	Sumitomo Pharma (Suzhou) Co., Ltd.	phase 3	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT7 receptor
Latuda©	Latuda©	University of North Carolina, Chapel Hill	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT7 receptor, serotonin 5-HT1A receptor
Latuda (Lurasidone)	Latuda (Lurasidone)	Massachusetts General Hospital	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT7 receptor
Lurasidone Oral Capsule	Lurasidone Oral Capsule	NeuroRx, Inc.	phase 3	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT7 receptor, Serotonin 5-HT1A receptor
Lurasidone 20, 40, 60, 80 mg, flexibly dosed	Lurasidone 20, 40, 60, 80 mg, flexibly dosed	Sumitomo Pharma America, Inc.	phase 3	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT7 receptor
Lurasidone HC1	Lurasidone HC1	Sumitomo Pharma America, Inc.	phase 3	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT7 receptor
SAMIDORPHAN L-MALATE	SAMIDORPHAN L-MALATE		marketed	Atypical Antipsychotic [EPC]	dopamine and serotonin type 2 (5HT2) receptors, opioid receptors	2021-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

Shanghai Mental Health Center · 10 drugs in this class
AstraZeneca · 6 drugs in this class
Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
Eli Lilly and Company · 4 drugs in this class
Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
Medical University of Vienna · 2 drugs in this class
Organon and Co · 2 drugs in this class
Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
H. Lundbeck A/S · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lurasidone tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/lurasidone-tablets. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab